• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

中国人对癌症预防与治疗的支付意愿:对成本效益阈值的影响。

Willingness to pay for cancer prevention versus treatment in China: implications for cost-effectiveness threshold.

机构信息

Department of Public Administration, School of Health Economics and Management, Nanjing University of Chinese Medicine, Nanjing, China.

Department of Science and Education of the Fourth Affiliated Hospital, and Center for Health Policy Studies, School of Public Health, Zhejiang University School of Medicine, Hangzhou, China.

出版信息

Expert Rev Pharmacoecon Outcomes Res. 2024 Jan;24(1):155-160. doi: 10.1080/14737167.2023.2262141. Epub 2024 Jan 18.

DOI:10.1080/14737167.2023.2262141
PMID:37754783
Abstract

BACKGROUND

Empirical support for the appropriate cost-effectiveness threshold (CET) in China remains sparse.

OBJECTIVE

This study aimed to estimate the willingness to pay (WTP) for cancer prevention and treatment from the perspective of healthcare policy-makers (i.e. supply side) and to investigate whether there is a difference between the estimated WTP in two scenarios.

METHODS

We conducted a web-based survey from May to July 2022 among experts who offering consultation to the government. We surveyed 79 experts from a national think-tank (84.81% response rate) using contingent valuation method, a method for estimating the monetary value that individuals place on a non-market service.

RESULTS

The mean WTP for two scenarios were estimated at 1.29 times of per capita Gross Domestic Product (GDP) of China and 1.90 times of per capita GDP, respectively. There was a difference between the WTP in the two scenarios and the WTP for treatment was significantly higher than prevention.

CONCLUSION

The findings suggest that though there is a smaller gap between the two scenarios in China as compared to other countries, the WTP may vary under different scenarios. So there's a need to further refine the development of CET by adding parameters like prevention instead of defining one universal threshold.

摘要

背景

在中国,实证支持适当的成本效益阈值(CET)的证据仍然很少。

目的

本研究旨在从医疗保健政策制定者(即供应方)的角度估计癌症预防和治疗的支付意愿(WTP),并探讨在两种情况下估计的 WTP 是否存在差异。

方法

我们于 2022 年 5 月至 7 月期间,使用条件价值评估法(一种用于估计个人对非市场服务的货币价值的方法),对向政府提供咨询的专家进行了一项基于网络的调查。我们对来自一个国家智库的 79 名专家进行了调查(响应率为 84.81%)。

结果

两个情景的平均 WTP 分别估计为中国人均国内生产总值(GDP)的 1.29 倍和 1.90 倍。两种情况下的 WTP 存在差异,治疗的 WTP 明显高于预防。

结论

研究结果表明,尽管中国两种情况下的差距比其他国家小,但在不同情况下 WTP 可能会有所不同。因此,需要通过添加预防等参数进一步完善 CET 的制定,而不是定义一个通用的阈值。

相似文献

1
Willingness to pay for cancer prevention versus treatment in China: implications for cost-effectiveness threshold.中国人对癌症预防与治疗的支付意愿:对成本效益阈值的影响。
Expert Rev Pharmacoecon Outcomes Res. 2024 Jan;24(1):155-160. doi: 10.1080/14737167.2023.2262141. Epub 2024 Jan 18.
2
Estimating the cost-effectiveness threshold of advanced non-small cell lung cancer in China using mean opportunity cost and contingent valuation method.运用平均机会成本法和条件价值评估法估算中国晚期非小细胞肺癌的成本效益阈值。
Cost Eff Resour Alloc. 2023 Nov 2;21(1):80. doi: 10.1186/s12962-023-00487-z.
3
Estimating the range of incremental cost-effectiveness thresholds for healthcare based on willingness to pay and GDP per capita: A systematic review.基于支付意愿和人均 GDP 估算医疗保健增量成本效益阈值范围:系统评价。
PLoS One. 2022 Apr 14;17(4):e0266934. doi: 10.1371/journal.pone.0266934. eCollection 2022.
4
Willingness to Pay for One Additional Quality Adjusted Life Year: A Population Based Survey from China.支付意愿以获得额外一年质量调整生命年:来自中国的一项基于人群的调查。
Appl Health Econ Health Policy. 2022 Nov;20(6):893-904. doi: 10.1007/s40258-022-00750-z. Epub 2022 Aug 8.
5
A systematic review of studies eliciting willingness-to-pay per quality-adjusted life year: does it justify CE threshold?对获取每质量调整生命年支付意愿的研究进行的系统评价:这是否能证明成本效益阈值的合理性?
PLoS One. 2015 Apr 9;10(4):e0122760. doi: 10.1371/journal.pone.0122760. eCollection 2015.
6
Estimation of the value of curative therapies in oncology: a willingness-to-pay study in China.肿瘤学中治愈性疗法价值的评估:一项在中国的支付意愿研究。
Cost Eff Resour Alloc. 2023 Jun 5;21(1):37. doi: 10.1186/s12962-023-00442-y.
7
Establishing cost-effectiveness threshold in China: a community survey of willingness to pay for a healthylife year.在中国建立成本效益阈值:一项关于健康生活年支付意愿的社区调查。
BMJ Glob Health. 2024 Jan 9;9(1):e013070. doi: 10.1136/bmjgh-2023-013070.
8
Willingness to pay for one quality-adjusted life year in Iran.伊朗对一个质量调整生命年的支付意愿。
Cost Eff Resour Alloc. 2019 Feb 28;17:4. doi: 10.1186/s12962-019-0172-9. eCollection 2019.
9
Evaluation of willingness to pay per quality-adjusted life year for a cure: A contingent valuation method using a scenario-based survey.评估治愈每质量调整生命年的支付意愿:一种基于情景调查的条件价值评估方法。
Medicine (Baltimore). 2018 Sep;97(38):e12453. doi: 10.1097/MD.0000000000012453.
10
Monetary value of health-a practical decision-making framework combining equity considerations and WTP.健康的货币价值——一个结合公平考量与支付意愿的实用决策框架
Eur J Health Econ. 2025 Mar;26(2):183-198. doi: 10.1007/s10198-024-01693-z. Epub 2024 May 20.

引用本文的文献

1
Patient willingness to pay and preference for cervical cancer treatments among middle- and low-income populations in Xinjiang.新疆中低收入人群对宫颈癌治疗的支付意愿和偏好
J Patient Rep Outcomes. 2025 Aug 21;9(1):107. doi: 10.1186/s41687-025-00938-6.